The company has a long presence in therapeutics for the disease, with drugs like TNF inhibitor Humira ... “The prevalence of IBD continues to increase, and many people living with ulcerative ...
A much older drug, Stelara, is already approved to treat several IBD indications, including CD and UC, across the United States and the European Union. J&J added more than $8 billion from Stelara ...
28,787 people played the daily Crossword recently. Can you solve it faster than others?28,787 people played the daily Crossword recently. Can you solve it faster than others?
Teva's R&D chief, Eric Hughes, didn't hold back, calling the results beyond expectations, while Sanofi's head of R&D, Houman Ashrafian, described the drug as a frontier in treating IBD.
and Crohn's disease (CD), the two main types of inflammatory bowel disease (IBD). The study met its primary endpoints for both diseases. In the UC group, 36.2% of patients who received a low dose ...